OTCPK:BRSY.F

Stock Analysis Report

Executive Summary

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Brainsway's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.0%

BRSY.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

BRSY.F

9.9%

US Medical Equipment

0.7%

US Market

No trading data on BRSY.F.

No trading data on BRSY.F.


Share holder returns

BRSY.FIndustryMarket
7 Day-2.0%1.1%-0.6%
30 Day-2.0%1.3%2.9%
90 Day-2.0%3.0%1.3%
1 Yearn/a10.8%9.9%2.9%0.7%
3 Year1.6%1.6%70.1%64.9%44.6%35.2%
5 Year-54.5%-54.5%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Brainsway's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Brainsway undervalued based on future cash flows and its price relative to the stock market?

3.74x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Brainsway to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Brainsway to establish if it is available at substantial discount.


Price Based on Earnings

Brainsway is loss making, we can't compare its value to the US Medical Equipment industry average.

Brainsway is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Brainsway, we can't assess if its growth is good value.


Price Based on Value of Assets

Brainsway is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Brainsway expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

23.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Brainsway's revenue is expected to grow significantly at over 20% yearly.

Brainsway is not considered high growth as it is expected to be loss making for the next 1-3 years.

Brainsway's revenue growth is expected to exceed the United States of America market average.

Unable to compare Brainsway's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Brainsway's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Brainsway will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Brainsway performed over the past 5 years?

-11.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Brainsway does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Brainsway's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Brainsway's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Brainsway has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Brainsway has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Brainsway improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Brainsway's financial position?


Financial Position Analysis

Brainsway is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Brainsway's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Brainsway has no debt.

Brainsway currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

High level of physical assets or inventory.

Brainsway has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Brainsway has sufficient cash runway for more than 3 years based on current free cash flow.

Brainsway has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 27.4% each year.


Next Steps

Dividend

What is Brainsway's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Brainsway's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Brainsway's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Brainsway has not reported any payouts.

Unable to verify if Brainsway's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Brainsway has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Brainsway's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

David Zacut (66yo)

0yrs

Tenure

US$177,000

Compensation

Dr. David Zacut, MD, serves as Interim Chief Executive Officer of Brainsway Ltd. since September 2019. Dr. Zacut founded Brainsway Ltd. in 2006 and has been its Chairman since 2006. Dr. Zacut served as an  ...


Management Age and Tenure

4.0yrs

Average Tenure

47yo

Average Age

The tenure for the Brainsway management team is about average.


Board Age and Tenure

8.0yrs

Average Tenure

61yo

Average Age

The tenure for the Brainsway board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Avi Posen (52yo)

    Vice President of Global Sales

    • Tenure: 4.1yrs
  • David Zacut (66yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$177.00k
  • Ronen Segal (46yo)

    Chief Technology Officer

    • Tenure: 2.8yrs
    • Compensation: US$281.00k
  • Hadar Levy (45yo)

    CFO & COO

    • Tenure: 5yrs
    • Compensation: US$325.00k
  • Avraham Zangen (49yo)

    Co-Founder

    • Tenure: 0.3yrs
    • Compensation: US$75.00k
  • Yiftach Roth (48yo)

    Founder & Chief Scientist

    • Tenure: 13.7yrs
    • Compensation: US$108.00k
  • Joe Perekupka (46yo)

    Senior VP of Sales & Operations North America

    • Tenure: 0yrs
    • Compensation: US$252.00k
  • Aron Tendler

    Chief Medical Officer

    • Tenure: 3.9yrs
  • Moria Ankri (35yo)

    Vice President Research & Development

    • Tenure: 2yrs
    • Compensation: US$169.00k

Board Members

  • Karen Sarid (69yo)

    Director

    • Tenure: 1.8yrs
  • David Zacut (66yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$177.00k
  • Avner Hagai (63yo)

    Founder & Vice-Chairman of the Board

    • Tenure: 12.8yrs
    • Compensation: US$30.00k
  • Avraham Zangen (49yo)

    Co-Founder

    • Tenure: 0.3yrs
    • Compensation: US$75.00k
  • Daniel Azriel (67yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: US$1.41k
  • Gavriel Magen (58yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: US$1.55k
  • Orly Uri (59yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$10.25k
  • Eti Mitrany (49yo)

    Director

    • Tenure: 3.3yrs
  • Mark George

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • David Feifel

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Brainsway Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Brainsway Ltd.
  • Ticker: BRSY.F
  • Exchange: OTCPK
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪409.816m
  • Listing Market Cap: ₪116.435m
  • Shares outstanding: 22.24m
  • Website: https://www.brainsway.com

Number of Employees


Location

  • Brainsway Ltd.
  • Bynet Building
  • 3rd Floor
  • Jerusalem
  • 9777518
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BWAYTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2007
BRSY.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2007
BWAYNasdaqGM (Nasdaq Global Market)SPONSORED ADSUSUSDApr 2019

Biography

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:02
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.